BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Supernus Pharmaceuticals Raises $35 Million


7/30/2009 7:56:44 AM

Transaction Brings Total Raised Against Royalties to more than $110 Million

Company Adds Mazindol to Pipeline as Potential Treatment for ADHD

ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. today announced that it recently closed a second non-dilutive financing transaction that brings the total funds raised to date against royalties from its partnered products to more than $110 million. In April 2008, the company announced a $75 million transaction secured by royalties generated from partnered products using Supernus technologies.

"We are pleased to be able to raise a significant amount of cash in this challenging environment to further develop our pipeline and accelerate our progress towards becoming a leading specialty pharmaceutical company treating diseases of the central nervous system (CNS),” said Jack Khattar, President and Chief Executive Officer.

“In addition, we have expanded our R&D portfolio to include mazindol as a potential treatment for ADHD,” Khattar said. “We have in-licensed significant intellectual property in the ADHD area and believe mazindol could be a promising new treatment.”

About Supernus

Supernus Pharmaceuticals, Inc. is focused on developing specialty CNS products designed to improve patient compliance, reduce side effects, and address unmet medical needs. The company currently has two epilepsy products in late-stage development, with Epliga™ in Phase III and Trokesa™ expected to enter Phase III in the next few months. Both products are designed to offer epilepsy patients an effective anti-convulsant therapy with much-needed lower side effects and the convenience of once-per-day dosing. In addition, the company is developing a portfolio of three products including mazindol in the ADHD area.

The company's extensive expertise in product development is well proven over the past 19 years. Supernus started its operations in December 2005 when it purchased significantly all the assets of Shire Laboratories, Inc. Products using the technologies and expertise of Supernus, and when formerly Shire Laboratories, include: Adderall XR®, Carbatrol® and Equetro®, which are marketed by Shire or its sub-licensees; and Oracea® and Sanctura® XR, which are marketed by Galderma and Allergan, respectively.

All trademarks are the property of their respective owners.

Supernus Pharmaceuticals, Inc.

Russell (Rip) Wilson, 301-838-2522

Chief Financial Officer

www.supernus.com




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES